Objective. Access to pregabalin via Ontario's public drug insurance program was expanded to an unrestricted model on April 1, 2013, from a prior authorization model. This study aims to identify the effect of expanded access on the rate of pregabalin use by publicly insured persons and to assess the characteristics of new patients initiating pregabalin following this expanded access.
Introduction
Pregabalin is an anticonvulsant drug that is indicated for the treatment of pain associated with a number of conditions such as diabetic neuropathy and is one of multiple recommended treatment options in pain management guidelines [1] [2] [3] [4] . Compared with gabapentin, an older anticonvulsant also used in pain management, pregabalin carries some advantages, including a lower risk of sedation and a linear pharmacokinetic profile [5] [6] [7] . Its antinociceptive effects are thought to be due to inhibition of calcium-dependent neurotransmitter release and interactions with descending noradrenergic and serotonergic pathways [8] [9] [10] . In Canada and the United States, pregabalin is indicated for the treatment of pain related to fibromyalgia and neuropathic pain associated with diabetic neuropathy, spinal cord injury, or postherpetic neuralgia [6, 10] . As this study was conducted in Ontario, Canada, on-label usage will be defined as the official Health Canada indications. In the United States, it is also indicated as adjunct therapy for partial seizures in adults [10] . Although pregabalin has been shown to be effective for improving pain in these conditions, examining the trends in pregabalin use following expanded coverage is of clinical importance as it may lead to increased off-label usage and concomitant usage with other central nervous system (CNS)-depressing drugs, potentially leading to increased side effects and cost [1, 3, 4, [11] [12] [13] [14] [15] [16] [17] .
The Ontario Drug Benefit Program (ODB) is a public insurance program that covers the cost of prescription medications for eligible residents of Ontario. Prior to April 1, 2013, pregabalin was covered by the ODB through its Exceptional Access Program (EAP), a prior-authorization model in which patients had to meet specific criteria prior to applying for pregabalin coverage. Patients eligible for EAP coverage of pregabalin were neuropathic pain patients who experienced an ineffective response or intolerable side effects or had contraindications to adequate trials of tricyclic antidepressants or gabapentin. On April 1, 2013, pregabalin was added to the ODB formulary as a general benefit, eliminating the requirement for patients to meet criteria for reimbursement.
We set out to evaluate the impact of expanded access to pregabalin on patterns of prescribing and drug use in Ontario and to identify whether individuals newly initiating pregabalin following the policy change were being treated for unapproved indications or in combinations with other medications that may be unsafe.
Methods

Setting and Design
We conducted a cross-sectional time series analysis examining the use of pregabalin by residents of Ontario, Canada, who were eligible for the Ontario Public Drug Program (OPDP) from April 1, 2006 , to December 31, 2014. In Ontario, individuals are eligible for prescription drug coverage if they are unemployed, receive disability support, have high prescription drug costs relative to net household income, receive home care services, reside in a long-term care facility, or are over the age of 65 years. We then conducted a secondary analysis among patients initiating pregabalin therapy between April 1, 2013, and March 31, 2014, to describe the characteristics of newly initiated users and prevalence of concomitant medication use. All ODB-eligible individuals have universal access to prescription drug coverage, physician services, and hospital care in Ontario. This study was approved by the Research Ethics Board of Sunnybrook Hospital, Toronto, Ontario.
Data Sources
We identified prescription drug claims for pregabalin using the Ontario Drug Benefit (ODB) database. The ODB database is collected for reimbursement purposes and has been demonstrated to have an error rate of less than 1% [18] . We obtained hospitalization data from the Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD), which contains detailed clinical information regarding all inpatient hospital admissions, and data on emergency department visits from the CIHI National Ambulatory Care Reporting System (CIHI-NACRS). We identified patients with diabetes using the Ontario Diabetes Database, and demographic data was obtained from the Registered Persons Database, a registry of all Ontario residents with publicly funded health insurance. Physicians' services were identified using the Ontario Health Insurance Plan physician claims data. These databases were linked in an anonymous fashion using encrypted Ontario health card numbers, were analyzed at the Institute for Clinical Evaluative Sciences, and are routinely used to study drug safety [19, 20] .
Identification of Patients and Outcomes
In our primary analysis, we identified all ODB-eligible individuals who were dispensed a prescription for pregabalin and the total costs of pregabalin prescriptions in each quarter of the study period. We excluded patients with invalid identifiers and those with missing age information. This population was divided into two groups, those younger than age 65 years, and those age 65 years or older. The rates of pregabalin use in both groups were then examined and compared over time.
In our secondary analysis, we identified all new users of pregabalin over a one-year period between April 1, 2013, and March 31, 2014. New users were defined among those age 66 years of age and older as those with no pregabalin prescription in the 365 days prior to cohort entry. To ensure ODB eligibility in the younger age group (65 years and under), we required individuals to have filled a prescription for any drug in the past 181 to 365 days and defined new users as those without any prescription for pregabalin in the past 365 days. As the ODB will only cover a maximum of 100 days' supply of each medication at a time, the 365-day lookback period is generally considered to be an appropriate method for identifying pregabalin initiation [21] [22] [23] . In order to exclude individuals who filled a prescription but never actually took the medication and to ensure that we were accurately analyzing patients who truly initiated pregabalin, we further restricted new pregabalin users to those who were dispensed a second prescription for pregabalin within 120 days following their initial prescription [21, 22, 24] .
Among the cohort of new pregabalin users, we defined patient characteristics at cohort entry, including general demographic information (age and gender), any past diagnosis of fibromyalgia, diabetes, or seizure disorders within the five years prior to cohort entry, and select Johns Hopkins Adjusted Clinical Groups System (ACG) expanded diagnosis clusters (musculoskeletal, neurological, cardiovascular, renal, or psychosocial) based on health services utilization in the past two years [25] . Use of pregabalin to treat postherpetic neuralgia was estimated by identifying diagnoses of herpes zoster using the CIHI-DAD, CIHI-NACRS, and OHIP databases in the year prior to cohort entry. We also identified the number of physician visits and the prevalence of a neurologist visit in the year prior to cohort entry.
We examined patterns of use of other medications prior to and following pregabalin initiation. Specifically, we identified recent prior use, concomitant use, and potential discontinuation of opioids, gabapentin, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants, acetaminophen, benzodiazepines, and oral corticosteroids. Prior medication use was defined as any medication dispensed in the 365 days prior to, but not including, the cohort entry date. Concomitant medication use was defined during the first year of pregabalin therapy as medications prescribed between the cohort entry date and the earlier of either one year following cohort entry or pregabalin discontinuation. Because the maximum dispensed duration of an ODB-reimbursed prescription in Ontario is 100 days, we defined pregabalin discontinuation on the basis of no prescription dispensed within 120 days of the prior prescription to allow for some flexibility in timing of refills and nonadherence to prescribed medication regimens [24] . Potential discontinuation of other medications was defined as prior use of a medication with no indication of concomitant use. We stratified our analysis of new users by age (<66 and 66 years) to assess differences in characteristics between age groups. To compare the effect of pregabalin initiation on opioid use, we also identified the median daily dose of opioid prescriptions, in morphine equivalents, before and after patients started pregabalin. We identified opioid prescriptions for patients starting from one year before pregabalin initiation to the end of either the study period or discontinuation of pregabalin.
Results
Between April 2006 and December 2014, a total of 108,047 ODB-eligible individuals were prescribed pregabalin. In the first quarter (Q1) of 2013, prior to expanded access on the Ontario formulary, only 1.0 per 1,000 ODBeligible individuals was treated with pregabalin, rising to 22.0 per 1,000 ODB-eligible individuals by Q4 of 2014. A significant portion of this observed increase took place within the first quarter of pregabalin funding implementation, resulting in nearly a 10-fold increase in usage rates in Q2 of 2013 compared with Q1. When stratified by age, the rate of pregabalin use in ODB-beneficiaries younger than age 65 years increased over 15-fold from 1.8 per 1,000 individuals in Q1 2013 to 28.6 per 1,000 individuals in Q4 2014. Among ODB beneficiaries age 65 years or older, the rate increased even more dramatically, rising nearly 30-fold from 0.7 per 1,000 individuals in Q1 2013 to 19.7 per 1,000 individuals in Q4 2014. The rate of pregabalin use was consistently greater in patients younger than age 65 years throughout the study period except for a single quarter, Q2 of 2013, immediately following expanded access where the rate of use in the older group was greater by 0.06 per 1,000 individuals (Figure 1) . The overall rising prevalence of use had considerable impacts on the costs of pregabalin prescriptions in Ontario, rising from $1,186,884 per quarter just prior to expanded access on the formulary, to $5,376,398 in the final quarter of 2014.
We identified a total of 56,471 ODB-eligible individuals from the cohort above who newly initiated pregabalin between April 1, 2013, and March 31, 2014. Of these, 39,789 (70.5%) were dispensed a second prescription for pregabalin within 120 days after the first and were included in the analysis. The median age of this cohort was 70 years, 38.8% were male, and 14.9% had a neurologist visit in the past year. We found a large proportion of new pregabalin users with a history of musculoskeletal (81.6%) and neurological (68.1%) diagnoses. Despite the high prevalence of musculoskeletal history in our cohort, only 20.1% had a previous musculoskeletal diagnosis without a neurological or fibromyalgia diagnosis. A history of neurological diagnoses including seizure disorders was found in 3.1% of new pregabalin users. Furthermore, 14.2% of new users had a diagnosis of fibromyalgia and 4.9% had a diagnosis of herpes zoster in the year prior to initiating pregabalin. We also found that 72.0% of new pregabalin users had either a neurological or fibromyalgia diagnosis (Table 1) .
In the year prior to pregabalin initiation, there was a high prevalence of use of opioids (58.9%), antidepressants (52.9%), NSAIDs (39.6%), and benzodiazepines (30.2%), and the majority of these individuals continued these medications after initiating pregabalin (Figure 2 ). More specifically, the use of opioids dropped from 58.9% to 54.8%, the use of antidepressants from 52.9% to 49.5%, and the use of benzodiazepines from 30.2% to 27.2%. There was, however, a larger decrease in the use of NSAIDs, which fell from 39.6% to 31.7% by 12 months following initiation or discontinuation of pregabalin. Appropriately, gabapentin was used by 19.3% of new pregabalin users prior to pregabalin initiation, but concomitant use of both products was rare (5.9%) (Figure 2 ). The daily opioid dose prescribed, in morphine equivalents, remained consistent both before (median ¼ 45 mg MEQ, IQR ¼ 23-90 mg MEQ) and after (median ¼ 43 mg MEQ, IQR ¼ 23-90 mg MEQ) initiation of pregabalin (standardized difference ¼ 0.02).
Discussion
In this study spanning almost nine years, the primary analysis identified a nearly 10-fold increase in the rate of pregabalin use in the quarter following its addition to the public drug formulary in April 2013. The drastic increase was observed in both patients younger than age 65 years and those age 65 years or older and continued to the end of the study period. This observation is consistent with prior studies that have been conducted in other jurisdictions that found greater pregabalin use in populations with unrestricted access compared with similar populations or periods of time where pregabalin access was restricted [26] [27] [28] .
Our analysis of new pregabalin users suggests that pregabalin is largely being prescribed for the official Health Canada indications of neuropathic pain and pain related to fibromyalgia, as neurological (68.1%) and musculoskeletal diagnoses (81.6%) were the most prevalent conditions identified. This is further supported by the high prevalence of use of other medications such as opioids and antidepressants among these new users that are commonly used to treat neuropathic pain. To estimate on-label use, we used the prevalence of either a neurological or fibromyalgia diagnosis, for which we found a rate of 72.0%. However, as a result of broad inclusion of a number of diagnoses under our definition of neuropathic conditions, we expect this is an overestimate of true on-label use, and off-label use is likely high. For example, although not as common as the official Health Canada indications, we found that approximately 1,250 new users of pregabalin in Ontario had a prior neurological diagnosis and a seizure disorder (3.1%), a condition for which pregabalin is indicated in the United Kingdom and the United States but not in Canada [6, 10, 29] . We also found that one in five new pregabalin users had a musculoskeletal diagnosis without any neurological or fibromyalgia diagnoses, which may be suggestive of off-label pregabalin use for other types of pain. Although we had initially expected pregabalin to act as a replacement for many drugs currently used to treat chronic neuropathic pain, this was not supported by the results as opioid use remained high, being used by 54.8% (compared with a prior usage rate of 58.9%) of patients initiating pregabalin, with the median daily opioid dose remaining consistent both before (median ¼ 45 mg MEQ) and after (median ¼ 43 mg MEQ) initiation of pregabalin. The use of antidepressants and benzodiazepines also remained high following pregabalin initiation. We did observe that some patients discontinued use of gabapentin, NSAIDs, and oral corticosteroids following pregabalin initiation, which is encouraging considering the significant side effects of these medications.
Despite the fairly low cost of pregabalin now that generic formulations are available, further investigation is needed to accurately assess the cost-effectiveness of pregabalin as our results have shown that it is generally being added to existing medication regimens rather than being used as an alternative to current treatments. As for the high rates of concomitant drug therapy using opioids, antidepressants, and benzodiazepines after initiating pregabalin, we believe that some of it may be attributable to a deficiency of knowledge or awareness of other modalities of pain treatment such as complementary, physical, or psychological treatments, which have the potential to reduce dependence on pharmacologic approaches [30] .
Limitations
Several limitations of this analysis merit discussion. First, we were unable to assess the use of any medications (over-the-counter or prescription) paid for out of pocket or by private insurance, including any prescriptions for pregabalin prior to its addition to the ODB formulary that were not covered by the EAP. This may result in an Drug Insurance Policy and Pregabalin Use underestimation of prior or concomitant medication use in the cohort and an overestimation of the effects of the policy change on the number of users of pregabalin as some of these individuals may have been accessing pregabalin through other means during this time. Second, the generalizability of our results is restricted to the elderly and younger individuals with low socioeconomic status who are eligible for public drug coverage.
Although an estimated 60% of Ontarians have private drug insurance, this number largely represents those who would not be covered by ODB such as those from a family in which a member has drug insurance benefits from full-time employment [31] . Therefore, although some of the observed rise in pregabalin use may be due to individuals switching from private insurance or cash payments to reimbursement through ODB, we do not expect this to substantially contribute to the 22-fold increase in use that we observed in this study. Third, our detection methods which rely on diagnosis records may result in an underestimation of the prevalence of fibromyalgia as its general and vague symptoms can contribute to underdiagnosis [32, 33] . Although this may cause an overestimation of the proportion of patients with musculoskeletal conditions unrelated to fibromyalgia, we do not believe it to have an impact on the overall interpretation of our results as it is unlikely that undiagnosed fibromyalgia alone can account for the 20.1% prevalence of musculoskeletal diagnoses in new pregabalin users without either neurological or fibromyalgia diagnoses. Finally, our study only identified medication use in the year prior to starting pregabalin, and so it may not have captured medications that were discontinued earlier due to intolerance or other reasons. We were also unable to identify the dosing intensity of medications other than opioids used by our study population, which may have changed following initiation of pregabalin.
Conclusions
In summary, we found a 22-fold increase in the overall rate of pregabalin use among Ontarians eligible for public drug coverage over a period of 21 months following the expansion of access to pregabalin. The use of opioids and other CNS-depressing drugs remained high in patients who initiated pregabalin following expanded access, raising the risk of CNS side effects and drug interactions due to concomitant use. Although a considerable portion of pregabalin use appears to be for approved indications, the results of this study suggest that there may be some degree of off-label use for conditions such as seizure disorders in Canada and, more importantly, other types of musculoskeletal pain beyond fibromyalgia. As expanded access to pregabalin increased its use in combination with other chronic neuropathic pain management medications, potentially Prevalence of concomitant use of other medication among new pregabalin users Figure 2 Prevalence of prior use, concomitant use, and potential discontinuation of other medications among new users of pregabalin. Prior use of another medication class was defined as filling of a prescription for a medication belonging to one of the identified classes within 365 days prior to the first prescription for pregabalin dispensed. Potential discontinuations of another medication class were defined as prior use without another fill of a medication from the same class following initiation of pregabalin. Concomitant use of a medication class was defined as a dispensed prescription from one of the medication classes within the earlier of 1) 365 days following the first dispensing of pregabalin for a patient or 2) discontinuation of pregabalin (120 days without a subsequent refill).
resulting in increased costs to the public health system and side effects, further research would be helpful in identifying the benefits and cost-effectiveness of expanded access to pregabalin in order to guide future funding decisions for other medications.
